113 related articles for article (PubMed ID: 2526150)
1. Determination of phosphonoformate (foscarnet) in biological fluids by ion-pair reversed-phase liquid chromatography.
Pettersson KJ; Nordgren T; Westerlund D
J Chromatogr; 1989 Mar; 488(2):447-55. PubMed ID: 2526150
[TBL] [Abstract][Full Text] [Related]
2. Determination of phosphonoformic acid in human plasma and urine by high-performance liquid chromatography with electrochemical detection.
Hassanzadeh MK; Aweeka FT; Wu S; Jacobson MA; Gambertoglio JG
J Chromatogr; 1990 Jan; 525(1):133-40. PubMed ID: 2140113
[TBL] [Abstract][Full Text] [Related]
3. Determination of foscarnet (trisodium phosphonoformate) in pharmaceutical preparations by high-performance liquid chromatography with ultraviolet detection.
García J; Márquez A; Ruiz R; López LF; Claro C; Lucero MJ
Biomed Chromatogr; 2006 Oct; 20(10):1024-7. PubMed ID: 16583452
[TBL] [Abstract][Full Text] [Related]
4. Determination of N-(phosphonacetyl)-L-aspartic acid (PALA) in plasma and urine by high pressure liquid chromatography.
Lankelma J; Penders PG; Leyva A; Pinedo HM
Eur J Cancer (1965); 1980 Nov; 16(11):1483-7. PubMed ID: 7227423
[No Abstract] [Full Text] [Related]
5. Clinical experiences with phosphonoformate (foscarnet) treatment of viral diseases following renal transplantation.
Ahlmén J; Wijnween AC; Brynger H; Lycke E
Scand J Urol Nephrol Suppl; 1985; 92():41-4. PubMed ID: 3008316
[TBL] [Abstract][Full Text] [Related]
6. In vitro inhibition of Herpesvirus sylvilagus by phosphonoacetic acid and phosphonoformate.
Goodrich JM; Lee KW; Hinze HC
Arch Virol; 1980; 66(3):261-4. PubMed ID: 6449917
[TBL] [Abstract][Full Text] [Related]
7. Effect of sodium phosphonoformate on blood group antibody detection.
Douglas R
Vox Sang; 1987; 53(1):61. PubMed ID: 2958968
[No Abstract] [Full Text] [Related]
8. Effect of sodium phosphonoformate on blood group antibody detection.
Hunt AF; Jones MT; Howkins GJ
Vox Sang; 1986; 51(3):231-2. PubMed ID: 2949433
[TBL] [Abstract][Full Text] [Related]
9. The potential of phosphonoformate for the treatment of herpex simplex labialis.
Oxford J
J Antimicrob Chemother; 1980 Nov; 6(6):694-5. PubMed ID: 6449499
[No Abstract] [Full Text] [Related]
10. Quantitation of the antitumor agent N-(phosphonacetyl)-L-aspartic acid in human plasma and urine by gas chromatography-mass spectrometry-selected ion monitoring.
Branfman AR; Bruni RJ; Merrill YN; Chadwick M; Strong JM; Ervin TJ
J Chromatogr; 1980 May; 182(2):163-9. PubMed ID: 7380909
[TBL] [Abstract][Full Text] [Related]
11. [Antiviral activity of phosphonoacetic acid, phosphonopropionic acid, and trisodium phosphonoformate hexahydrate against herpesvirus hominis type 1 and type 2 in vitro].
Thiel KD; Wutzler P; Sprössig M; Bertram D
Pharmazie; 1982 Aug; 37(8):608. PubMed ID: 6292963
[No Abstract] [Full Text] [Related]
12. Mode of interference of trisodium phosphonoformate (INN: foscarnet sodium), with influenza virus mRNA synthesis.
Stridh S; Datema R
Virology; 1984 May; 135(1):293-6. PubMed ID: 6233785
[TBL] [Abstract][Full Text] [Related]
13. In vitro recovery of resistant retrovirus isolates after exposure to phosphonoformate.
Muratore O; Varnier OE; Raffanti SP; Schito GC
Eur J Clin Microbiol; 1984 Oct; 3(5):447-9. PubMed ID: 6238823
[No Abstract] [Full Text] [Related]
14. Successful treatment with trisodium phosphonoformate for primary cytomegalovirus infection after heart transplantation.
Locke TJ; Odom NJ; Tapson JS; Freeman R; McGregor CG
J Heart Transplant; 1987; 6(2):120-2. PubMed ID: 3040944
[TBL] [Abstract][Full Text] [Related]
15. Effects of foscarnet on the cell kinetics of Madin-Darby canine kidney cells.
Stenberg K; Skog S; Tribukait B
Biochim Biophys Acta; 1983 Feb; 762(1):31-5. PubMed ID: 6219711
[TBL] [Abstract][Full Text] [Related]
16. Foscarnet as treatment for cytomegalovirus retinitis following bone marrow transplantation.
Ganly PS; Arthur C; Goldman JM; Schulenburg WE
Postgrad Med J; 1988 May; 64(751):389-91. PubMed ID: 2849092
[TBL] [Abstract][Full Text] [Related]
17. Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study.
Barton SE; Munday PE; Kinghorn GR; van der Meijden WI; Stolz E; Notowicz A; Rashid S; Schuller JL; Essex-Cater AJ; Kuijpers MH
Genitourin Med; 1986 Aug; 62(4):247-50. PubMed ID: 2942457
[TBL] [Abstract][Full Text] [Related]
18. Determination of N-(Phosphonacetyl)-L-aspartic acid (PALA) in dog serum and urine by gas chromatography and selected lon monitoring.
Strong JM; Kinney YE; Branfman AR; Cysyk RL
Cancer Treat Rep; 1979 May; 63(5):775-80. PubMed ID: 455314
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effect of trisodium phosphonoformate on the mean plaque size of pseudorabies virus, infectious bovine rhinotracheitis virus and pigeon herpesvirus.
Schwers A; Pastoret PP; Vindevogel H; Leroy P; Aguilar-Setien A; Godart M
J Comp Pathol; 1980 Oct; 90(4):625-33. PubMed ID: 6268670
[No Abstract] [Full Text] [Related]
20. Inhibition of cytomegalovirus late antigens by phosphonoformate.
Wahren B; Oberg B
Intervirology; 1980; 12(6):335-9. PubMed ID: 6244238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
